Is Alpha-Lipoic Acid Effective in the Treatment of Diabetic Polyneuropathy?
DOI: 10.3238/zfa.2019.0294-0297german translation / full article
QuestionDiabetic polyneuropathy is a common consequence of diabetes mellitus. Alpha-lipoic acid is frequently recommended as a first line treatment. Do we have reliable evidence from clinical trials regarding this treatment option?AnswerOverall evidence from clinical trials is unsatisfactory. The quality of the existing studies is limited, observation periods are too short, the number of cases investigated is too low, and surrogate endpoints are predominantly used. Symptomatic improvement appears to be possible, but high-quality studies with larger numbers of participants are necessary to prove this effect. A therapeutic try-out seems justified if standard therapy is unsuccessful, but a general recommendation of alpha-lipoic acid cannot be given.